The pharmaceutical arena is evolving similarly to the development of new medicines as companies implement better, streamlined processes to optimise sourcing, adherence to regulatory requirements, manufacturing and global distribution; all of which make them more competitive in a constantly changing business environment. Profitably harnessing the three pillars that are rapidly redefining the pharmaceutical sector, comparator drug supply, pharmaceutical licensing services and contract manufacturing consultants, coupled with active pharmaceutical ingredient suppliers, represents a critical need in today’s marketplace and will afford businesses with greater capability of decreasing risk, improving efficiencies and enhancing scalability.
By integrating each of the three pillars into their respective business models, pharmaceutical companies can not only create operational efficiencies but also establish themselves as market leaders with a distinct competitive edge in an increasingly crowded and heavily regulated marketplace. The blog post will further discuss how pharmaceutical companies can leverage the three pillars into competitive advantages as they continue to operate in an ever-evolving global environment.
The Shift from Linear Operations to Integrated Ecosystems
Pharmaceutical development has typically occurred linearly, from discovery through development, manufacture, and finally commercialisation. Historically, each function within a pharmaceutical organisation operated independently of the others, resulting in inefficiencies, delays, and compliance risks.
That model of pharmaceutical development is now obsolete.
Modern success in the pharmaceutical industry depends upon integrating the many workflows of a business together. As an example, if a company sources comparators, then clinical timelines are prepared based on that information, the licensing of a product impacts the clinical development programme, and the manufacturing process of a product affects the cost and scale at which the product can be produced.
If an organisation does not strategically integrate all of these factors, it will experience:
- Clinical trial delays
- Regulatory bottlenecks
- Production cost increases
- Supply chain interruptions
Conversely, those organisations that are strategically aligned with their integrated processes possess agility and resiliency.
Comparator Drug Supply: A Strategic Lever, Not Just a Requirement
In clinical research, it is critical to supply comparator drugs as part of an overall study design, especially with bioequivalence and comparative efficacy studies. Herein lies a major error: treating the supply of comparator drugs as a simple procurement activity. This mistake can be very expensive.
Why Comparator Drug Supply is Important – Now More Than Ever
The global clinical research trial environment has become increasingly complicated as a result of:
- Regional trial design
- Increasing regulatory scrutiny (e.g. greater scrutiny of the sourcing process).
- Increased demand for niche/specialised drugs
As a result of these complexities, comparator drug supply has evolved into a strategic function that has a direct impact upon:
- Trial timelines
- Success of regulatory approvals
- Efficiency of the budget
Potential Challenges in Comparator Drug Supply
- Global Sourcing Limitations: Originator drugs may not be available in certain geographical locations
- Product Verification & Traceability: The sourcing process needs to ensure that the drugs being sourced are actually what is being requested
- Shipping & Temperature Control: The challenge of the cold chain
- Regulatory Compliance: Addressing the country-specific regulatory requirements.
Strategic Approach to Achieving Optimal Comparator Drug Supply
The forward-thinking organisation has shifted to:
- Developing partnerships with specialised sourcing suppliers
- Developing regional comparator drug supply hubs
- Implementing the use of digital tracking systems
- Early alignment of comparator drug supply strategies with clinical protocols.
Once developed correctly, a comparator drug supply becomes an accelerator of time and a risk reduction tool.
Pharma Licensing Service: Unlocking Market Access with Precision
Pharmaceutical companies face serious challenges when expanding internationally due to vast variances in regulations and the resulting difficulty in obtaining approvals for their products.
The value of using a pharmaceutical licensing service goes far beyond simply providing documentation.
New Strategic Value of Licensing
Licensing is no longer merely the completion and submission of forms to obtain an approved license for a product. It now entails developing a marketing strategy to enter that market while being compliant with regulatory obligations, understanding the competitive environment, and achieving business goals.
What Pharma Licensing Services Do
They provide:
- Creating the regulatory dossier and submitting it to the regulatory body.
- Obtaining product registrations in numerous countries.
- Managing the product from its introduction until its discontinuation, which includes renewal requirements.
- Ensuring that products are labelled and comply with regulatory requirements.
- Assisting clients with their changes to a product post-approval and applying for and obtaining the required approvals.
How Companies Use Pharma Licensing Services to Gain Competitive Advantage
Companies that utilise the services of an experienced pharmaceutical licensing service provider will benefit from:
- Shorter product approval times
- Reduced risk of regulatory non-compliance
- More accurate and compliant product approvals
- Smooth global product expansion
Key Trends Affecting Pharma Licensing
- Accelerated harmonisation across regulatory agencies.
- Development of electronic submission systems.
- Real-time monitoring of compliance with approved products.
- Increased emphasis on assessing the efficacy of integrating pharmacovigilance into pharmaceutical products and other systems.
As such, licensing should no longer be viewed solely as a regulatory obligation, but also as an opportunity to create an entry point to a new, high-growth, internationally-based marketplace.
The Role of a Contract Manufacturing Consultant in Strategic Growth
The financial and operational results of a specific product in the pharmaceutical market can all hinge on the decision made during the manufacturing process. Outsourcing is commonplace; yet, there are many factors to consider when moving through the actual manufacturing process.
Accessing a contract manufacturing consultant serves to be the intermediary between the pharmaceutical company and contract manufacturer while aligning all three important aspects (quality, cost and scalability).
The Importance of Expanding Consultant Expertise Today
As the contract manufacturing industry continues to grow and evolve into a very large, fragmented market, there are a variety of available capabilities, compliance standards, and cost structures. Therefore, if the company you are contracting with does not meet your requirements, you may experience:
- Regulatory compliance failures
- Product recalls
- Financial losses
- Delayed product commercialisation
The Benefits of Using a Contract Manufacturing Consultant
Vendor Identification and Qualification
- Cost Benchmarking and Negotiation
- Quality Audits and Compliance Checks
- Risk Assessment and Mitigation Strategies
- Project Management (From start to finish)
Overall Strategic Impact
The consultant’s active participation evolves the traditional view that manufacturing provides only a transactional service, to a long-term value-added partnership by providing:
- A Faster Time-to-Market
- Cost-effective Options
- Scalable Manufacturing Models
- Regulatory Assurance
The Power of Integration: Creating a Unified Pharma Strategy
All three elements: comparator sourcing, licensing, and manufacturing on their own are all very powerful in their own right. However, it’s only when these three strategies are executed together as part of a single strategy that they truly realise their potential.
Reasons Why Integration Supports Success
- Improved Efficiency: Alignment of sourcing, licensing & manufacturing timelines leads to less time lost due to delays.
- Reduced Costs: Coordinating the planning of sourcing, licensing, & manufacture helps to eliminate duplications and waste.
- Regulatory Assurance: Documentation and compliance can be consistent across all functions.
- Operational Flexibility: The ability to rapidly change in response to market and/or regulatory changes.
Real-World Outcomes From Companies Implementing Integrated Strategies
- 30% Reduction in Time-To-Market
- Significant Cost Savings Across Supply Chains
- Greater Chance of Clinical Trial Success
- Greater Ability to Expand Globally
Risk Management: Building Resilience in Uncertain Times
Disruption in the pharmaceutical market is prevalent on numerous occasions; major disruptions stem from geopolitical factors. unrest or by means of manufacturing disruptions.
The following are key areas of risk:
- Shortage of comparative drugs
- Unpredictable regulatory changes
- Manufacturing delays and quality compliance issues
The following may be utilised to assist w/ mitigation of these issues:
- Diversified sourcing networks.
- Stronger relationships between pharma companies and licensing agencies.
- Utilising experienced contractors.
- Having a reliable source for 1st & 3rd party contract manufacturers.
Being able to maintain a resilient business model is becoming a competitive advantage.
Conclusion
The pharmaceutical market is changing dramatically. Scientific innovation alone will not determine an organisation’s success anymore, but rather their ability to perform across a complex, interconnected ecosystem.
Organisations can create a sustainable and competitive edge by moving comparator drug supply from a procurement engine to a strategic operation; using pharma licensing services as a means of growing their global footprint; utilising contract manufacturing consulting partners as trustworthy resources to help them make appropriate manufacturing choices; and enhancing the scalability and quality of their active pharmaceutical ingredient contract manufacturing contracts.
So what is the question now? The question has therefore changed from whether you should adopt these strategies to how fast you can implement them.
That is because in today’s pharmaceutical environment, integration is much more than an advantage; it is the building block of success!